Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder (MDD,) providing further evidence of the psychedelic’s antidepressant capabilities.

Led by a research team from institutions including Yale, Johns Hopkins, NYU Langone and San Francisco Veterans Affairs Medical Center and published in the Journal of the American Medical Association (JAMA,) outcomes reveal that psilocybin was well-tolerated and elicited fast, solid and long-lasting efficacy results. 

The reportedly largest Phase 2, randomized, double-blind, placebo-controlled study of a single psilocybin dose to treat MDD followed participants for six weeks and took place between Dec. 2019 and June 2022. 

The 25mg dose paired with psychological support was associated with a significant reduction in depressive symptoms at day …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.